Home LiteratureArticle Details
PMID: 25177151 Published · epublish English Journal Article Review

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.

Breast cancer (Dove Medical Press) ·Vol. 6 ·2014-00-00 ·Pages 123-33

Cadoo KA, Gucalp A, Traina TA

Abstract

Cellular proliferation, growth, and division following DNA (deoxyribonucleic acid) damage are tightly controlled by the cell-cycle regulatory machinery. This machinery includes cyclin-dependent kinases (CDKs) which complex with their cyclin partners, allowing the cell cycle to progress. The cell-cycle regulatory process plays a critical role in oncogenesis and in the development of therapeutic resistance; it is frequently disrupted in breast cancer, providing a rational target for therapeutic development. Palbociclib is a potent and selective inhibitor of CDK4 and -6 with significant activity in breast cancer models. Furthermore, it has been shown to significantly prolong progression-free survival when combined with letrozole in the management of estrogen receptor-positive metastatic breast cancer. In this article we review the cell cycle and its regulatory processes, their role in breast cancer, and the rationale for CDK inhibition in this disease. We describe the preclinical and clinical data relating to the activity of palbociclib in breast cancer and the plans for the future development of this agent.

Keywords
CDK4/6 inhibition cell-cycle regulation cyclin-dependent kinases
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Cadoo Karen A
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA.
Gucalp Ayca
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA.
Traina Tiffany A
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA.
References (40)
40 references, click to expand
  1. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
    Cancer Res. 2002 Dec 1;62(23):6916-23 PMID: 12460907
  2. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.
    Endocr Relat Cancer. 2011 Apr 28;18(3):333-45 PMID: 21367843
  3. A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen.
    Cell Cycle. 2011 Mar 15;10(6):956-62 PMID: 21358261
  4. Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression.
    PLoS One. 2010 Jun 08;5(6):e11011 PMID: 20543978
  5. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
    Br J Cancer. 2004 May 17;90(10):1942-8 PMID: 15138475
  6. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.
    Oncogene. 2009 Apr 16;28(15):1812-20 PMID: 19287456
  7. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
    Oncogene. 2010 Jul 15;29(28):4018-32 PMID: 20473330
  8. Cyclin-dependent kinase 4/6 inhibition in cancer therapy.
    Cell Cycle. 2012 Nov 1;11(21):3913 PMID: 23032266
  9. Modification of the DNA damage response by therapeutic CDK4/6 inhibition.
    J Biol Chem. 2012 Aug 17;287(34):29075-87 PMID: 22733811
  10. Epithelial-mesenchymal transition induced by senescent fibroblasts.
    Cancer Microenviron. 2012 Apr;5(1):39-44 PMID: 21706180
  11. RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.
    Cell Cycle. 2010 Dec 1;9(23):4607 PMID: 21260944
  12. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.
    Cancer Res. 2008 Jul 15;68(14):5628-38 PMID: 18632615
  13. The senescence-associated secretory phenotype: the dark side of tumor suppression.
    Annu Rev Pathol. 2010;5:99-118 PMID: 20078217
  14. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.
    Am J Clin Pathol. 2005 Jan;123(1):21-7 PMID: 15762276
  15. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.
    J Clin Invest. 2010 Jul;120(7):2528-36 PMID: 20577054
  16. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
    Breast Cancer Res. 2009;11(5):R77 PMID: 19874578
  17. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    J Natl Cancer Inst. 2012 Mar 21;104(6):476-87 PMID: 22302033
  18. Comprehensive molecular portraits of human breast tumours.
    Nature. 2012 Oct 4;490(7418):61-70 PMID: 23000897
  19. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  20. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.
    Expert Rev Anticancer Ther. 2012 Dec;12(12):1579-89 PMID: 23253223
  21. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.
    J Clin Invest. 2007 Jan;117(1):218-28 PMID: 17160137
  22. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.
    Am J Pathol. 2011 Sep;179(3):1171-8 PMID: 21756866
  23. CDK-independent activation of estrogen receptor by cyclin D1.
    Cell. 1997 Feb 7;88(3):405-15 PMID: 9039267
  24. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
    Cell Cycle. 2012 Jul 15;11(14):2747-55 PMID: 22751436
  25. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
    Cancer Discov. 2011 Sep;1(4):338-51 PMID: 22049316
  26. Targeting the cell cycle: a new approach to cancer therapy.
    J Clin Oncol. 2005 Dec 20;23(36):9408-21 PMID: 16361640
  27. The retinoblastoma protein and cell cycle control.
    Cell. 1995 May 5;81(3):323-30 PMID: 7736585
  28. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
    PLoS One. 2013 Nov 12;8(11):e78641 PMID: 24265703
  29. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Clin Cancer Res. 2012 Jan 15;18(2):568-76 PMID: 22090362
  30. RB in breast cancer: at the crossroads of tumorigenesis and treatment.
    Cell Cycle. 2007 Mar 15;6(6):667-71 PMID: 17361100
  31. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).
    Br J Cancer. 2011 Jun 7;104(12):1862-8 PMID: 21610706
  32. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition.
    Cancer Res. 2008 Jul 1;68(13):5104-12 PMID: 18593909
  33. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.
    Oncogene. 2002 Jul 11;21(30):4680-90 PMID: 12096344
  34. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
    Mol Cancer Ther. 2004 Nov;3(11):1427-38 PMID: 15542782
  35. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.
    Ann Oncol. 2009 Nov;20(11):1818-23 PMID: 19556322
  36. Senescent cells as a source of inflammatory factors for tumor progression.
    Cancer Metastasis Rev. 2010 Jun;29(2):273-83 PMID: 20390322
  37. Methylation and Immunoexpression of p16(INK4a) Tumor Suppressor Gene in Primary Breast Cancer Tissue and Their Quantitative p16(INK4a) Hypermethylation in Plasma by Real-Time PCR.
    Korean J Pathol. 2012 Dec;46(6):554-61 PMID: 23323106
  38. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
    N Engl J Med. 2012 Feb 9;366(6):520-9 PMID: 22149876
  39. Cyclin D1 in breast cancer pathogenesis.
    J Clin Oncol. 2005 Jun 20;23(18):4215-24 PMID: 15961768
  40. Regulation of hormonal therapy resistance by cell cycle machinery.
    Gene Ther Mol Biol. 2008 Jan 1;12:395 PMID: 20148177
Article Info
Journal
Breast cancer (Dove Medical Press)
Abbr.
Breast Cancer (Dove Med Press)
ISSN
1179-1314
DOI
10.2147/BCTT.S46725
Published
2014-00-00
Epub
2014-00-04
Pages
123-33
Language
English
Region
New Zealand
NLM ID
101591856
PMCID
PMC4128689
External Links
PubMed source DOI: 10.2147/BCTT.S46725 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2